发布于: 雪球转发:0回复:5喜欢:0

$礼来(LLY)$ 这是延期了?

We continue to expect FDA regulatory actions on Donanemab in Q4 2024

全部讨论

没有延迟?——We may have had some muffled sound during announced prepared remarks. regarding the timing of regulatory action on Donanemab. And as Dan mentioned, the timing is expected to be Q1 of 2024 this year. Received some notes that there were some muffled sound, so I just wanted to clarify from that important point.